IL5 and asthma: In total, 60 patients with severe asthma and nasal polyposis who initiated therapy between 2018 and 2020 were identified, hereof 10 patients were not included in the analysis due to following reasons: Five patients (two anti‐IgE and three anti‐IL5/R treated) were excluded due to missing baseline symptom scores (SNOT‐20 and VAS), three patients (all anti‐Il4R treated) had not reached 6 months timepoint yet at time of database closure.